IRCT20170809035601N10 IRCT 2018-12-29 Esfahan University of Medical Sciences The effect of sedation of fentanyl-etomidate, fentanyl-propofol and fentanyl-midazolam in phacoamulsification Comparison of fentanyl-etomidate, fentanyl-propofol and fentanyl-midazolam for sedation in phacoemulsification 2017-11-01 anticipated 150 Complete https://irct.ir/trial/35734 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In the operating room, based on a random number table, one of the compounds of fentanyl- etomidate, fentanyl- propofol and fentanyl -midazolam is given to patients, Blinding description: In this study, both the participants and the outcomes Assessor were blind to the allocation of the participants into groups of fentanyl- etomidate, fentanyl- propofol and fentanyl -midazolam . The study drugs were prepared in 4 syringes covered with aluminum foil, by an anesthesiologist who was not involved in data collection. 2 Cataract surgery. Intervention 1: Intervention group: patients in group (E )received 0.1 mg/kg etomidate. In case of need, 4 mg etomidate will be injected as a rescue dose. At the end of the prescribed total dose is recorded. Intervention 2: Intervention group: patients in group (P) received 0.5 mg/kg propofol. In case of need, 20 mg propofol will be injected​ as a rescue dose. At the end of the prescribed total dose is recorded. Intervention 3: Intervention group: patients in group (M) received 0.04 mg/kg midazolam. In case of need, 2 mg midazolam will be injected as a rescue dose. At the end of the prescribed total dose is recorded. Yes - There is a plan to make this available What will be shared: The total potential data can be shared after unidentifiable people When: Start the access period one year after the publication of results To whom: Only available for scholars working in academic and academic centers Conditions: Use of data is permitted for the purpose of developing research on the use of the drug Where to obtain: To the email address of the corresponding author How to obtain: Within two weeks, the requested information will be provided to the applicant Comments: